Conference Day 1: Thursday 16th May 2019 @ 16:45

Real data from constitutive production and from continuous downstream purification of, eg., lentivirus and oncolytic viruses confirms these as key steps to improve consistency, robustness and reduced costs of goods for cell and gene therapy.

Conference Day 1: Thursday 16th May 2019 @ 17:00

How to look at the percentage empty vs filled viral particles Looking a potency of construct, how can this be measured and what are the tools? Infection of cell: analysing gene expression, functionality, level and potency

Dr Bo Kara, Head Process Development,GlaxoSmithKline

Bo Kara heads up the Process Development team for Advanced Therapy Delivery at GSK. He has over 25 years’ experience in designing research and development programmes to develop scaleable and validatable manufacturing processes for recombinant protein products. He has published widely and is primary ...